1,2-二氢-2-[((2-甲基-4-吡啶基)甲基]-1-氧代-8-(2-嘧啶基甲氧基)-4-(3,4,5-三甲氧基苯基)-2,7-萘啶-3-羧酸甲酯盐酸盐 | 324572-93-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 1,2-二氢-2-[((2-甲基-4-吡啶基)甲基]-1-氧代-8-(2-嘧啶基甲氧基)-4-(3,4,5-三甲氧基苯基)-2,7-萘啶-3-羧酸甲酯盐酸盐
• 英文名称: T 0156 hydrochloride
• 英文别名: methyl 2-[(2-methylpyridin-4-yl)methyl]-1-oxo-8-(pyrimidin-2-ylmethoxy)-4-(3,4,5-trimethoxyphenyl)-2,7-naphthyridine-3-carboxylate;hydrochloride
• CAS: 324572-93-2
• 化学式: C31H30ClN5O7
• 分子量: 620.0
• InChiKey: RBJCBXAXUHCWBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.42
• 重原子数：
  44
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  135
• 氢给体数：
  1
• 氢受体数：
  11

文献信息

• Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype
  申请人：Queens University at Kingston

  公开号：US20030215528A1

  公开（公告）日：2003-11-20

  The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.

  本发明涉及抑制、治疗和预防恶性细胞表型、细胞、肿瘤和/或疾病的方法和制剂。一氧化氮模拟物（如低剂量）的施用足以增加、恢复或维持细胞中一氧化氮介导的信号转导，从而抑制或预防恶性细胞表型、细胞、肿瘤和/或疾病。这些方法和制剂尤其适用于治疗和预防动物癌症。
• Combination therapy using antihypertensive agents and endothelin antagonists
  申请人：Queen's University at Kingston

  公开号：US20040063719A1

  公开（公告）日：2004-04-01

  The present invention provides a method for a more efficacious treatment of a vascular condition through the administration of a therapeutically effective amount of a combination of an anti-pressor agent, an endothelin antagonist, and a sex hormone for repetitive cycles of on/off-treatment. In one embodiment, the invention provides a method for the prevention of tolerance induced by an anti-pressor agent via the inclusion of an endothelin antagonist in a combination therapy approach to remodel vascular structure and treat vascular conditions associated with a male or female sexual dysfunction, atherosclerosis, renal failure, hypertension, congestive heart failure, diabetic nephropathy, and diabetic neuropathy. The anti-pressor agent comprises one or more compounds such as prostaglandin-E 1 , an ACE inhibitor, an angiotensin-II receptor antagonist, an &agr; 1 -adrenergic receptor antagonist, a &bgr;-adrenergic receptor antagonist, a calcium channel blocker, an activator of guanylyl cyclase or adenyl cyclase, a phosphodiesterase inhibitor, and hydralazine. The endothelin antagonist comprises one or more compounds such as a peptidal endothelin antagonist, a non-peptidal endothelin antagonist, and an inhibitor of endothelin converting enzyme. Such a combination therapy approach enhances the efficacy of the anti-pressor agent and enables an increase in the frequency and duration of anti-pressor administrations for the long term treatment of vascular conditions.

  本发明提供了一种更有效地治疗血管疾病的方法，通过给予治疗有效量的抗压剂、内皮素拮抗剂和性激素的组合，进行重复周期的开/关治疗。在一个实施方案中，本发明提供了一种通过在联合疗法中加入内皮素拮抗剂来预防由抗压迫剂诱发的耐受性的方法，以重塑血管结构并治疗与男性或女性性功能障碍、动脉粥样硬化、肾功能衰竭、高血压、充血性心力衰竭、糖尿病肾病和糖尿病神经病变相关的血管疾病。抗压剂包括一种或多种化合物，如前列腺素-E 1 ACE抑制剂、血管紧张素-II受体拮抗剂、&agr； 1 -肾上腺素能受体拮抗剂、&bgr;-肾上腺素能受体拮抗剂、钙通道阻滞剂、鸟苷酸环化酶或腺苷酸环化酶激活剂、磷酸二酯酶抑制剂和水合肼。内皮素拮抗剂包括一种或多种化合物，如肽类内皮素拮抗剂、非肽类内皮素拮抗剂和内皮素转化酶抑制剂。这种联合治疗方法提高了抗血管紧张素药物的疗效，并能增加抗血管紧张素药物的用药频率和用药时间，从而达到长期治疗血管疾病的目的。
• FORMULATIONS AND METHODS OF USING NITRIC OXIDE MIMETICS IN CANCER TREATMENT
  申请人：Cellegy Pharmaceuticals, Inc

  公开号：EP1492567A1

  公开（公告）日：2005-01-05
• Formulations and methods of using nitric oxide mimetics in cancer treatment
  申请人：Graham Charles H.

  公开号：US20110028543A1

  公开（公告）日：2011-02-03

  The present invention relates to methods and formulations for inhibiting, treating and preventing a malignant cell phenotype, cell, tumor and/or disease. Administration of nitric oxide mimetics, such as low doses, is sufficient to increase, restore or maintain nitric oxide-mediated signaling in cells so that malignant cell phenotypes, cells, tumors and/or diseases are inhibited or prevented. These methods and formulations are particularly useful in treating and preventing cancer in animals.
• METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR A LYMPHATIC MALFORMATION
  申请人：The Board of Trustees of the Leland Stanford Junio

  公开号：US20130345232A1

  公开（公告）日：2013-12-26

  Methods of treating lymphatic malformations using a phosphodiesterase type 5 inhibitor are provided. Pharmaceutical compositions and kits comprising phosphodiesterase type 5 inhibitors are also provided.